tetano
Editor, Senior Moderator
Clin Infect Dis
. 2021 Jul 10;ciab566.
doi: 10.1093/cid/ciab566. Online ahead of print.
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial
Fatimah S Dawood[SUP] 1 [/SUP], Allison L Naleway[SUP] 2 [/SUP], Brendan Flannery[SUP] 1 [/SUP], Min Z Levine[SUP] 1 [/SUP], Kempapura Murthy[SUP] 3 [/SUP], Suryaprakash Sambhara[SUP] 1 [/SUP], Shivaprakash Gangappa[SUP] 1 [/SUP], Laura Edwards[SUP] 4 [/SUP], Sarah Ball[SUP] 4 5 [/SUP], Lauren Beacham[SUP] 1 [/SUP], Edward Belongia[SUP] 6 [/SUP], Kelsey Bounds[SUP] 3 [/SUP], Weiping Cao[SUP] 1 [/SUP], F Liaini Gross[SUP] 1 [/SUP], Holly Groom[SUP] 2 [/SUP], Alicia M Fry[SUP] 1 [/SUP], Danielle Hunt[SUP] 4 [/SUP], Zuha Jeddy[SUP] 4 [/SUP], Margarita Mishina[SUP] 1 [/SUP], Sara S Kim[SUP] 1 [/SUP], Meredith G Wesley[SUP] 1 4 [/SUP], Sarah Spencer[SUP] 1 [/SUP], Mark G Thompson[SUP] 1 [/SUP], Manjusha Gaglani[SUP] 3 [/SUP]
Affiliations
Abstract
Background: RIV4 and cell-culture based inactivated influenza vaccine (ccIIV4) have not been compared to egg-based IIV4 in healthcare personnel, a population with frequent influenza vaccination that may blunt vaccine immune responses over time. We conducted a randomized trial among HCP aged 18-64 years to compare humoral immune responses to ccIIV4 and RIV4 to IIV4.
Methods: During the 2018-2019 season, participants were randomized to receive ccIIV4, RIV4, or IIV4 and had sera collected pre-vaccination, 1 and 6 months post-vaccination. Sera were tested by hemagglutination inhibition (HI) for influenza A/H1N1, B/Yamagata, and B/Victoria and microneutralization (MN) for A/H3N2 against cell-grown vaccine reference viruses. Primary outcomes at 1 month were seroconversion rate (SCR), geometric mean titers (GMT), GMT ratio, and mean fold rise (MFR) in the intention-to-treat population.
Results: 727 participants were included (283 ccIIV4, 202 RIV4, and 242 IIV4). At 1 month, responses to ccIIV4 were similar to IIV4 by SCR, GMT, GMT ratio, and MFR. RIV4 induced higher SCRs, GMTs, and MFRs than IIV4 against A/H1N1, A/H3N2, and B/Yamagata. The GMT ratio of RIV4 to egg-based vaccines was 1.5 (95%CI 1.2-1.9) for A/H1N1, 3.0 (95%CI 2.4-3.7) for A/H3N2, 1.1 (95%CI 0.9-1.4) for B/Yamagata, and 1.1 (95%CI 0.9-1.3) for B/Victoria. At 6 months, ccIIV4 recipients had similar GMTs to IIV4, whereas RIV4 recipients had higher GMTs against A/H3N2 and B/Yamagata.
Conclusion: RIV4 resulted in improved antibody responses by HI and MN compared to egg-based vaccines against three of four cell-grown vaccine strains 1 month post-vaccination, suggesting a possible additional benefit from RIV4.
Keywords: Influenza vaccines; healthcare personnel; immunogenicity.
. 2021 Jul 10;ciab566.
doi: 10.1093/cid/ciab566. Online ahead of print.
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial
Fatimah S Dawood[SUP] 1 [/SUP], Allison L Naleway[SUP] 2 [/SUP], Brendan Flannery[SUP] 1 [/SUP], Min Z Levine[SUP] 1 [/SUP], Kempapura Murthy[SUP] 3 [/SUP], Suryaprakash Sambhara[SUP] 1 [/SUP], Shivaprakash Gangappa[SUP] 1 [/SUP], Laura Edwards[SUP] 4 [/SUP], Sarah Ball[SUP] 4 5 [/SUP], Lauren Beacham[SUP] 1 [/SUP], Edward Belongia[SUP] 6 [/SUP], Kelsey Bounds[SUP] 3 [/SUP], Weiping Cao[SUP] 1 [/SUP], F Liaini Gross[SUP] 1 [/SUP], Holly Groom[SUP] 2 [/SUP], Alicia M Fry[SUP] 1 [/SUP], Danielle Hunt[SUP] 4 [/SUP], Zuha Jeddy[SUP] 4 [/SUP], Margarita Mishina[SUP] 1 [/SUP], Sara S Kim[SUP] 1 [/SUP], Meredith G Wesley[SUP] 1 4 [/SUP], Sarah Spencer[SUP] 1 [/SUP], Mark G Thompson[SUP] 1 [/SUP], Manjusha Gaglani[SUP] 3 [/SUP]
Affiliations
- PMID: 34245243
- DOI: 10.1093/cid/ciab566
Abstract
Background: RIV4 and cell-culture based inactivated influenza vaccine (ccIIV4) have not been compared to egg-based IIV4 in healthcare personnel, a population with frequent influenza vaccination that may blunt vaccine immune responses over time. We conducted a randomized trial among HCP aged 18-64 years to compare humoral immune responses to ccIIV4 and RIV4 to IIV4.
Methods: During the 2018-2019 season, participants were randomized to receive ccIIV4, RIV4, or IIV4 and had sera collected pre-vaccination, 1 and 6 months post-vaccination. Sera were tested by hemagglutination inhibition (HI) for influenza A/H1N1, B/Yamagata, and B/Victoria and microneutralization (MN) for A/H3N2 against cell-grown vaccine reference viruses. Primary outcomes at 1 month were seroconversion rate (SCR), geometric mean titers (GMT), GMT ratio, and mean fold rise (MFR) in the intention-to-treat population.
Results: 727 participants were included (283 ccIIV4, 202 RIV4, and 242 IIV4). At 1 month, responses to ccIIV4 were similar to IIV4 by SCR, GMT, GMT ratio, and MFR. RIV4 induced higher SCRs, GMTs, and MFRs than IIV4 against A/H1N1, A/H3N2, and B/Yamagata. The GMT ratio of RIV4 to egg-based vaccines was 1.5 (95%CI 1.2-1.9) for A/H1N1, 3.0 (95%CI 2.4-3.7) for A/H3N2, 1.1 (95%CI 0.9-1.4) for B/Yamagata, and 1.1 (95%CI 0.9-1.3) for B/Victoria. At 6 months, ccIIV4 recipients had similar GMTs to IIV4, whereas RIV4 recipients had higher GMTs against A/H3N2 and B/Yamagata.
Conclusion: RIV4 resulted in improved antibody responses by HI and MN compared to egg-based vaccines against three of four cell-grown vaccine strains 1 month post-vaccination, suggesting a possible additional benefit from RIV4.
Keywords: Influenza vaccines; healthcare personnel; immunogenicity.